OXFORD - Frustrated by the lack of substance in a House of Commons report on the Millargate affair, a British lawmaker is suggesting that Europe needs an independent watchdog to make sure that biotech companies do not mislead the public over drug trials.

Ian Gibson, a member of the House of Commons Science and Technology Committee that has been investigating the affair, is looking for ways to put a little more meat on the bones of what has been widely regarded as a weak report on the controversies surrounding British Biotech plc (LSE:BBG; BBIOY, Oxford, U.K.).